Plain-English translation of NCT07733674 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This early-stage trial is testing a new diagnostic imaging medication called 203Pb-RMX-VH-PIB in people with glioblastoma (an aggressive brain tumor) or pancreatic ductal adenocarcinoma (pancreatic cancer). You would receive a single injection of the medication, followed by imaging scans to help researchers understand how it moves through your body and which organs receive radiation exposure. The goal is to gather safety information and learn whether this medication could help doctors better see and treat these cancers in the future.
Current imaging methods may not always show tumors clearly enough to help doctors plan the best treatment. This trial is exploring whether the new medication can provide better images of brain and pancreatic tumors, which could lead to improved diagnosis and more targeted treatment options.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will come to the clinic for one visit where you will receive a single injection of the medication through an IV. Over the next several hours, you will undergo multiple whole-body imaging scans (SPECT/CT) to track how the medication moves through your body. Before and after the injection, the research team will check your vital signs, perform a heart rhythm test (ECG), and collect blood and urine samples. The study team will monitor you closely for any side effects for 30 days after receiving the medication.
AI-generated summary from trial data · Aug 20, 2026 · Not medical advice
United States